Get detailed information on Imatinib, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...

By Bulto’s estimate, some 30% to 40% of first-line patients today are being treated with Gleevec or generic imatinib. Novartis expects the first adopters of Scemblix in first-line CML will be ...

Tier Institutional Healthcare Investors -- -- Advancement of IkT-001Pro into a Late-Stage Clinical Trial Program in Pulmonary ...

Combination of ziftomenib and imatinib shows robust and durable antitumor activity in imatinib-sensitive (1L) and imatinib-resistant (2L/3L) GIST models – – Proof-of-concept study of ziftomenib plus ...

News on Inhibikase's promising treatments for PAH and Parkinson's Disease, supported by FDA approval and substantial funding.

Chronic myeloid leukaemia (CML) blockbuster Gleevec has been badly hit by generic competition in the US, revenues falling 30% to $834 million in the period. This decline will continue, with ...

Azurity Pharmaceuticals has earned FDA approval for Danziten (nilotinib), a new formulation of Novartis’ chronic myeloid ...

Important cases on prevention of evergreening of patents: 📍Novartis AG v. Union of India (2013): Novartis’ patent ...

Imatinib is a specific tyrosine kinase inhibitor which has been approved for the treatment of Philadelphia chromosome-positive chronic myeloid leukaemia and c-KIT (CD117)-positive gastrointestinal ...

Hypothesis: For this reason, finding new treatment approaches could be helpful. In this study, Imatinib was applied as a mast cell inhibitor to reduce pain crises in these patients. Seven patients ...